IRCT20220211053992N36尚未招募Unknown
In vivo bioequivalence study of Dolutegravir 50 mg tablets manufactured by Bakhtar Bioshimi Co. compared to innovator product
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 59 years（—）
- 性别
- All
入选标准
- •General Health (in terms of Liver, Heart and Kidney diseases)
- •Age between 18 to 59 years
排除标准
- •History of cardiovascular, liver, and kidney disease
- •Alcohol and drug addiction
- •History of drug allergy
研究者
相似试验
招募中
Unknown
Bioequivalence study of Dulotegravir 50 mg tabletIRCT20200105046010N102Sobhan trading group24
暂停
1 期
Bioequivalence Study of 50 mg Dolutegravir Film-coated Tablets in Healthy Thai VolunteersBioequivalence Study of 50 mg Dolutegravir Film-caoted Tablets in Healthy Thai VolunteersTCTR20220907001nison Laboratories Co., Ltd.30
尚未招募
Unknown
Benefits and safety of major medicines in HIV patients.CTRI/2024/04/065522Institute of Medical Sciences, Banaras Hindu University
撤回
4 期
Pharmacokinetics of single-dose dOLutegravir in HIV-serOnegative sub-jects with severe hepatic impairment compared to matched controls (POLO).NL-OMON47050Afdeling Apotheek15
已完成
3 期
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)Infection, Human Immunodeficiency VirusHIV InfectionsNCT02831673ViiV Healthcare719